Hims & Hers Stops Offering Semaglutide Drugs Following FDA Scrutiny

The company offered a compounded version of the drug that was not approved by the agency.
Hims & Hers Stops Offering Semaglutide Drugs Following FDA Scrutiny
The U.S. Food and Drug Administration (FDA) in White Oak, Md., on June 5, 2023.Madalina Vasiliu/The Epoch Times
|Updated:

Telehealth business Hims & Hers will stop offering customers pills made of compounded semaglutide, which is used for weight loss and diabetes control, the company said in a Feb. 7 post on X.

Compounded drugs are medications created by licensed pharmacists or physicians by mixing and combining the various ingredients of a drug. These are not approved by the Food and Drug Administration, as a result of which their safety, quality, and effectiveness remain suspect. Semaglutide is the active ingredient of medications such as Ozempic and Wegovy, which are GLP-1 drugs used to treat diabetes and weight loss.
Naveen Athrappully
Naveen Athrappully
Reporter
Naveen Athrappully is a news reporter covering business and world events at The Epoch Times.